51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2024-09, Vol.91 (3), p.AB37-AB37
Main Authors: Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0190-9622
DOI:10.1016/j.jaad.2024.07.155